Connection

ANDRAS HECZEY to Immunotherapy, Adoptive

This is a "connection" page, showing publications ANDRAS HECZEY has written about Immunotherapy, Adoptive.
Connection Strength

1.971
  1. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020 03; 8(3):309-320.
    View in: PubMed
    Score: 0.443
  2. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
    View in: PubMed
    Score: 0.370
  3. Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother Cancer. 2025 Jan 11; 13(1).
    View in: PubMed
    Score: 0.157
  4. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
    View in: PubMed
    Score: 0.155
  5. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.149
  6. Selective refueling of CAR T?cells using ADA1 and CD26 boosts antitumor immunity. Cell Rep Med. 2024 May 21; 5(5):101530.
    View in: PubMed
    Score: 0.149
  7. GD2-CAR CAR T?cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter. Cancer Cell. 2024 01 08; 42(1):8-10.
    View in: PubMed
    Score: 0.146
  8. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
    View in: PubMed
    Score: 0.140
  9. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690.
    View in: PubMed
    Score: 0.117
  10. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
    View in: PubMed
    Score: 0.108
  11. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55.
    View in: PubMed
    Score: 0.021
  12. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.